This study is designed to combine anti-angiogenic drugs on the basis of PD-L1+ gemcitabine/cisplatin, hoping to further improve the curative effect of advanced BTC treatment and provide more choices for first-line treatment of BTC in China.
1.Age range from 18 to 80 years old, regardless of gender;
2.Histologically confirmed, unresectable advanced or metastatic BTC including cholangiocarcinoma (intrahepatic or extrahepatic), gallbladder carcinoma.
3. Patients who have not received systematic treatment for BTC in the past .
4.At least one measurable lesion (according to RECIST v1.1 requirements).
1. Histologically diagnosed as neuroendocrine carcinoma;
2. People who are allergic to adebelizumab, apatinib, gemcitabine, cisplatin or their auxiliary materials;
3. Systemic treatment in the past;
4. Pleural effusion, pericardial effusion or ascites accompanied by clinical symptoms and judged by the researcher to require frequent drainage;